Adapting a Behavioral Program to Prevent FASD and Harmful Infant Outcomes in SA
Official title: Adapting and testing a behavioral intervention to prevent FASD and adverse infant outcomes
Funded at Philadelphia College of Osteopathic Med · NIH-11525904 · Data updated 2026-11-12
A program is being adapted and tested to help pregnant and breastfeeding women in South Africa reduce alcohol, tobacco, and cannabis use to prevent fetal alcohol spectrum disorder and other infant problems.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Philadelphia College of Osteopathic Med NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $212,501 |
| NIH project number | 7R33AA030043-04 |
| Project ID | NIH-11525904 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pregnant or breastfeeding women in South Africa who use alcohol and/or tobacco or cannabis.
✕Less likely to help
Women who are not using substances or who are not pregnant/breastfeeding may not directly benefit.
What this research studies
This project tailors an evidence-based behavioral approach to lower polysubstance use during pregnancy and breastfeeding in South Africa. It aims to reduce the risk of fetal alcohol spectrum disorder and other adverse birth outcomes by addressing alcohol and co-occurring substance use. The study plans to adapt contingency management approaches and integrate them with local care settings to support women through pregnancy and lactation. Results will inform how to implement effective, culturally appropriate support for reducing prenatal substance exposure. The work involves collaboration with local health systems to test feasibility and impact.
Why it matters
Potential benefit: If successful, the program could reduce fetal alcohol exposure and improve infant development and health outcomes.
How similar studies have gone: Contingency management has reduced prenatal substance use in other settings, suggesting potential effectiveness in this context.
Where this research is happening
-
Philadelphia College of Osteopathic Med
Philadelphia, United States Active
Researchers
- Principal investigator: Washio, Yukiko — Philadelphia College of Osteopathic Med
- Study coordinator: Washio, Yukiko
Related research
Other NIH-funded projects on the same topics.
-
Adapting and testing a behavioral program to prevent FASD and adverse infant outcomes
A behavioral program is being tailored and tested to help pregnant and breastfeeding women reduce alcohol and other substance use to protect babies in South Africa.
-
CD38 and muscle energy in spinal and bulbar muscular atrophy
The team is trying to lower CD38 to boost muscle energy and help men with spinal and bulbar muscular atrophy (SBMA).
-
Investigating CD38 as a potential treatment target for spinal and bulbar muscular atrophy
This study is looking at a condition called spinal and bulbar muscular atrophy (SBMA) that mainly affects men, and it aims to find out how a specific enzyme called CD38 might help improve energy in muscle cells, which could lead to new treatments for people with this condition.
-
Creating a zebrafish model to study a genetic neuromuscular disease.
This study is creating a special zebrafish model to help find new treatments for spinal and bulbar muscular atrophy (SBMA), a genetic disease that mainly affects men, so researchers can quickly test potential therapies in a way that's both fast and affordable.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.